Clara Téllez Quijorna

Clara studied Biology (2017) at the University of Salamanca. Her international experience began with an Erasmus fellowship, during which she worked as a research student at Masaryk University in Brno, Czech Republic. This experience led her to extend her stay, working as a laboratory technician at the CEITEC Institute, also in Brno, where she studied RNA processing and degradation.

She then returned to Spain to complete her Master’s in Cellular and Molecular Biology (2019) at the University of Malaga, focusing on the anti-tumoral effects of a novel compound in breast cancer cell lines for her final master’s thesis. In 2020, she received a Marie Skłodowska-Curie fellowship to pursue her PhD at the CRCM Centre (Marseille, France). Her doctoral research focused on identifying a novel epigenetic biomarker and studying the role of the histone linker variant H1.3 in Acute Myeloid Leukemia (AML) (2024). This work contributes to understanding epigenetic regulation in AML and its impact on patient survival. As part of a European network, she had the opportunity to join the Department of Biology and Biotechnology at Sapienza University (Rome, Italy) for one month, studying the effects of several epigenetic drugs on AML cells.

She has recently joined the retrovirology and clinical studies team, where she works as a senior technician.